keryx inks $100M deal with Japan Tobacco (Will this $$ 20MM they get in April give this stock some movement UP???)
September 26, 2007
Tags experimental therapy Phase II
Tools
* Email
* Print
* Comment
* Contact Author
Japan Tobacco and its subsidiary Torii Pharmaceutical will pay up to $100 million for the Japanese licensing rights to Keryx's experimental therapy for high phosphorous levels in the blood. Up to $20 million of that money will become available by April, 2008. The drug, Zerenex, is in Phase II clinical trials in the U.S.
"They have proven themselves to be ideal partners for smaller U.S.-based biotechnology companies seeking development and commercial partners in Japan," said Michael S. Weiss, chairman and CEO of Keryx, about his new partners.
http://www.fiercebiotech.com/story/keryx...